COVID-19 pandemic in Russia

Swedish company ZandCell offers Russia 750 million dose vaccine capacity for Sputnik V and Aurora

Retrieved on: 
Thursday, July 29, 2021
COVID-19 pandemic in Russia, COVID-19 vaccines, Clinical trials, Medicine, Gamaleya Research Institute of Epidemiology and Microbiology, Science and technology in Russia, Vaccination, Sputnik V COVID-19 vaccine, Mass media, Sputnik, COVID-19 vaccine, COVID-19 vaccination in India

"We want either Sputnik V vaccine from Gamaleya or Aurora from Vector Institute.

Key Points: 
  • "We want either Sputnik V vaccine from Gamaleya or Aurora from Vector Institute.
  • I believe Sputnik V is the best vaccine in the world right now.
  • We are ready to manufacture 750 million doses per year and we offer our capacity to Russia.
  • For more information on ZandCell email: [email protected]
    Please visit the company's website at ZandCell.com or follow @ZandCell on Twitter.

DGAP-News: T&T Group: Vietnam Government supports T&T Group in purchase of 40 million Sputnik V vaccine doses

Retrieved on: 
Thursday, July 22, 2021
COVID-19 pandemic in Russia, Medicine, COVID-19, Science and technology in Russia, Sputnik V COVID-19 vaccine, COVID-19 vaccine, Vaccination, COVID-19 vaccination in Albania, COVID-19 vaccination in Vietnam

HANOI, VIETNAM - Media OutReach - 22 July 2021 - On July 12, the Government of Vietnam issued Resolution No.

Key Points: 
  • HANOI, VIETNAM - Media OutReach - 22 July 2021 - On July 12, the Government of Vietnam issued Resolution No.
  • 73/NQ-CP allowing T&T Group to purchase Sputnik V vaccines from the Russian Federation without using funds from the State budget or Vietnam's COVID-19 Vaccine Fund.
  • The Government's resolution stated that, at the request of the vaccine manufacturer, the Government agreed to a proposal from the Ministry of Health to sign an agreement that relinquishes liability for the use of the Sputnik V vaccine.
  • Implementing the Government's resolution, the Ministry of Health sent an official dispatch to the Russian Direct Investment Fund (RDIF) to introduce them to the T&T Group to negotiate to buy 40 million doses of the Sputnik V vaccine.

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

Retrieved on: 
Tuesday, July 20, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Coronaviridae, Zoonoses, Variants of SARS-CoV-2, Antiviral drugs, COVID-19 pandemic in Russia, Severe acute respiratory syndrome coronavirus 2, COVID-19, SARS-CoV-2 Delta variant, Immunome, Coronavir

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing.

Key Points: 
  • Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing.
  • Furthermore, IMM-BCP-01 showed in-vitro activity via non-neutralizing mechanisms, such as complement fixation, which Immunome expects will enable viral clearance.
  • IMM-BCP-01s ability to maintain neutralizing activity against emerging SARS-CoV-2 variants, including the Delta variant, potentially positions our drug candidate as a long-term solution to the changing threat posed by COVID-19.
  • Currently, the delta variant accounts for a majority of coronavirus cases in the United States.

RDIF and Serum Institute of India, the world's largest vaccine manufacturer by volume, to start production of Sputnik vaccine at Company's facilities in September

Retrieved on: 
Tuesday, July 13, 2021
Medical specialties, Medicine, Health care, Adenoviridae, COVID-19 vaccines, Clinical trials, Vaccine controversies, COVID-19 pandemic in Russia, Serum Institute of India, Sputnik V COVID-19 vaccine, Adar Poonawalla, Kirill Dmitriev

SII is the world's largest company in terms of COVID vaccines production with over 500 million doses manufactured.

Key Points: 
  • SII is the world's largest company in terms of COVID vaccines production with over 500 million doses manufactured.
  • The first batch of Sputnik vaccine is expected to be produced at SII's facilities in September.
  • Kirill Dmitriev, CEO of the Russian Direct Investment Fund, commented:
    "RDIF is delighted to cooperate with Serum Institute of India, the world's largest vaccine manufacturer.
  • Adar Poonawalla, CEO of Serum Institute of India,commented:
    "I am delighted to partner with RDIF to manufacture the Sputnik vaccine.

Sputnik V vaccine elicits high IGG antibodies and neutralizing antibodies titers, a study in Argentina published in international Cell Reports Medicine journal shows

Retrieved on: 
Monday, July 12, 2021
COVID-19 vaccines, Vaccines, Clinical trials, Vaccination, Medicine, COVID-19 pandemic in Russia, Science and technology in Russia, Gamaleya Research Institute of Epidemiology and Microbiology, Sputnik V COVID-19 vaccine, Sputnik Light, COVID-19, Immunoglobulin G

The study has been published in an international peer-reviewed, open access Cell Reports Medicine journal: https://www.sciencedirect.com/science/article/pii/S2666379121002081

Key Points: 
  • The study has been published in an international peer-reviewed, open access Cell Reports Medicine journal: https://www.sciencedirect.com/science/article/pii/S2666379121002081
    The research evaluates SARS-CoV-2-specific antibody responses after vaccination of 288 healthcare workers with Sputnik V in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses among non-infected and previously infected individuals.
  • Among key findings in the article they note that the first dose of Sputnik V induced strong immune response in 94% of individuals previously not infected with COVID.
  • In authors' opinion, vaccination with only the first component of Sputnik V (Sputnik Light vaccine) is sufficient to protect previously infected individuals.
  • To date, Sputnik V has been registered in 67 countries globally with a total population of over 3.5 billion people.

Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium

Retrieved on: 
Friday, June 18, 2021
Coronaviridae, Sarbecovirus, Health sciences, Medicine, Zoonoses, Antiviral drugs, COVID-19 pandemic in Russia, Coronavir, Severe acute respiratory syndrome, Brilacidin, COVID-19

The MHSRS is an annual four-day scientific symposium sponsored by the U.S. Department of Defense.

Key Points: 
  • The MHSRS is an annual four-day scientific symposium sponsored by the U.S. Department of Defense.
  • The presentation on Brilacidin will be part of the Development of New Front Line Therapies to Prevent and Treat Non-SARS-CoV-2 Endemic Viral Diseases Breakout Session.
  • Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19.
  • A more complete description of these risk factors is included in the Companys filings with the Securities and Exchange Commission.

The Russian Direct Investment Fund : Sputnik V demonstrates 94.3% efficacy and high safety profile during the vaccination campaign in Bahrain

Retrieved on: 
Thursday, June 10, 2021
COVID-19 pandemic in Russia, Articles, Finance, Money, Science and technology in Russia, Sputnik V COVID-19 vaccine, Russian Direct Investment Fund, COVID-19 vaccine, Sovereign wealth fund, Vaccination, Ministry of Health, Kirill Dmitriev

MOSCOW, June 10, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces thedata of the Ministry of Health of the Kingdom of Bahrain on the Russian Sputnik V coronavirus vaccine confirming its safety and high efficacy during the vaccination campaign in the country.

Key Points: 
  • MOSCOW, June 10, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces thedata of the Ministry of Health of the Kingdom of Bahrain on the Russian Sputnik V coronavirus vaccine confirming its safety and high efficacy during the vaccination campaign in the country.
  • "Our data has confirmed the high efficacy and safety of Sputnik V during its use in Bahrain.
  • Sputnik V continues to play an important role in the Kingdom's ongoing and successful vaccination campaign, with 81% of the eligible population vaccinated so far."
  • Russian Direct Investment Fund (RDIF)is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors.

RDIF holds a meeting of its International Advisory Board with participation of the President of Russia Vladimir Putin as part of SPIEF-2021

Retrieved on: 
Saturday, June 5, 2021
Countries, World, Economy, Russian Direct Investment Fund, COVID-19 pandemic in Russia, Sputnik V COVID-19 vaccine, Vladimir Putin, St. Petersburg International Economic Forum, Russia, Sovereign wealth fund, Kirill Dmitriev, COVID-19 vaccination in Russia

SAINT PETERSBURG, June 5, 2021 /PRNewswire/ --Russian President Vladimir Putin and representatives of the investment community took part in the traditional meeting of The Russian Direct Investment Fund's (RDIF, Russia's sovereign wealth fund) International Advisory Board (IAB) held at the St. Petersburg International Economic Forum.

Key Points: 
  • SAINT PETERSBURG, June 5, 2021 /PRNewswire/ --Russian President Vladimir Putin and representatives of the investment community took part in the traditional meeting of The Russian Direct Investment Fund's (RDIF, Russia's sovereign wealth fund) International Advisory Board (IAB) held at the St. Petersburg International Economic Forum.
  • More than 30 investors from 17 countries with over $15 trillion of assets under management took part in the Board's meeting.
  • The coronavirus pandemic, the key topic on the global agenda, was also touched upon during the IAB meeting.
  • RDIF has established a wide network of international partnerships for the production of the Sputnik V vaccine.

RDIF: The Sputnik V vaccine helps San Marino to become the first country in Europe to defeat COVID and reduce the infection rate to zero

Retrieved on: 
Monday, May 10, 2021
COVID-19 pandemic in Russia, Finance, Money, Economy, Russian Direct Investment Fund, Sputnik V COVID-19 vaccine, Sovereign wealth fund, COVID-19 vaccination in Russia, Kirill Dmitriev

b'MOSCOW, May 10, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia\'s sovereign wealth fund) announces positive results achieved by San Marino in the fight against coronavirus thanks to the Russian Sputnik V vaccine with infection rate having fallen to zero level.

Key Points: 
  • b'MOSCOW, May 10, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia\'s sovereign wealth fund) announces positive results achieved by San Marino in the fight against coronavirus thanks to the Russian Sputnik V vaccine with infection rate having fallen to zero level.
  • Sputnik V is registered in 64 countries around the world with total population of over 3.2 billion people.
  • RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia\'s GDP.
  • RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn.

RDIF: Turkey becomes the 63rd country in the world to authorize Sputnik V

Retrieved on: 
Friday, April 30, 2021
COVID-19 pandemic in Russia, Adenoviridae, COVID-19 vaccines, Clinical trials, Sputnik V COVID-19 vaccine, Articles, Medicine, Life sciences, COVID-19 vaccine, Vaccination, Sputnik, COVID-19 vaccination in Russia

Turkey has become the 63rd country to authorize the use of Sputnik V. Total population of the countries where Sputnik V is approved for use exceeds 3.2 billion people.\nPost-vaccination studies in a number of countries demonstrate that SputnikV is the safest and most effective vaccine against coronavirus.

Key Points: 
  • Turkey has become the 63rd country to authorize the use of Sputnik V. Total population of the countries where Sputnik V is approved for use exceeds 3.2 billion people.\nPost-vaccination studies in a number of countries demonstrate that SputnikV is the safest and most effective vaccine against coronavirus.
  • Sputnik V ranks second among coronavirus vaccines globally in terms of the number of approvals issued by government regulators.\nRDIF had earlier reached an agreement with Turkey\'s Viscoran la pharmaceutical company to cooperate on production of Sputnik V in the country.
  • RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia\'s GDP.
  • RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn.